Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma.

@article{Brandes2012AppropriateEF,
  title={Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma.},
  author={Alba A Brandes and Enrico Franceschi and Thierry Gorlia and Wolfgang Wick and Andreas H. Jacobs and Brigitta G. Baumert and Martin J. van den Bent and Michael Weller and Roger Stupp},
  journal={European journal of cancer},
  year={2012},
  volume={48 6},
  pages={896-903}
}
The progression-free survival rate at 6 months (PFS-6) has long been considered the best end-point for assessing the efficacy of new agents in phase II trials in patients with recurrent glioblastoma. However, due to the introduction of antiangiogenic agents in this setting, and their intrinsic propensity to alter neuroradiological disease assessment by producing pseudoregression, any end-point based on neuroradiological modifications should be reconsidered. Further, statistically significant… CONTINUE READING

From This Paper

Topics from this paper.
10 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…